Your browser doesn't support javascript.
loading
Establishment of a high-content imaging assay for tau aggregation in hiPSC-derived neurons differentiated from two protocols to routinely evaluate compounds and genetic perturbations.
Bahnassawy, Lamiaa; Nicolaisen, Nathalie; Untucht, Christopher; Mielich-Süss, Benjamin; Reinhardt, Lydia; Ried, Janina S; Morawe, Martina P; Geist, Daniela; Finck, Anja; Käfer, Elke; Korffmann, Jürgen; Townsend, Matthew; Ravikumar, Brinda; Lakics, Viktor; Cik, Miroslav; Reinhardt, Peter.
Afiliação
  • Bahnassawy L; Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany.
  • Nicolaisen N; Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany.
  • Untucht C; Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany.
  • Mielich-Süss B; Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany.
  • Reinhardt L; Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany.
  • Ried JS; Genomics Research Center, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany.
  • Morawe MP; Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany.
  • Geist D; Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany.
  • Finck A; Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany.
  • Käfer E; Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany.
  • Korffmann J; Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany.
  • Townsend M; Cambridge Research Center, AbbVie Inc., 200 Sidney Street, Cambridge, MA 02139, USA.
  • Ravikumar B; Cambridge Research Center, AbbVie Inc., 200 Sidney Street, Cambridge, MA 02139, USA.
  • Lakics V; Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany.
  • Cik M; Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany. Electronic address: miroslav.cik@abbvie.com.
  • Reinhardt P; Neuroscience Discovery, AbbVie Deutschland GmbH & Co KG, Knollstrasse, 67061 Ludwigshafen am Rhein, Germany. Electronic address: peter.reinhardt@abbvie.com.
SLAS Discov ; 29(2): 100137, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38128829
ABSTRACT
Aberrant protein aggregation is a pathological cellular hallmark of many neurodegenerative diseases, such as Alzheimer's disease (AD) and frontotemporal dementia (FTD), where the tau protein is aggregating, forming neurofibrillary tangles (NFTs), and propagating from neuron to neuron. These processes have been linked to disease progression and a decline in cognitive function. Various therapeutic approaches aim at the prevention or reduction of tau aggregates in neurons. Human induced pluripotent stem cells (hiPSCs) are a very valuable tool in neuroscience discovery, as they offer access to potentially unlimited amounts of cell types that are affected in disease, including cortical neurons, for in vitro studies. We have generated an in vitro model for tau aggregation that uses hiPSC - derived neurons expressing an aggregation prone, fluorescently tagged version of the human tau protein after lentiviral transduction. Upon addition of tau seeds in the form of recombinant sonicated paired helical filaments (sPHFs), the neurons show robust, disease-like aggregation of the tau protein. The model was developed as a plate-based high content screening assay coupled with an image analysis algorithm to evaluate the impact of small molecules or genetic perturbations on tau. We show that the assay can be used to evaluate small molecules or screen targeted compound libraries. Using siRNA-based gene knockdown, genes of interest can be evaluated, and we could show that a targeted gene library can be screened, by screening nearly 100 deubiquitinating enzymes (DUBs) in that assay. The assay uses an imaging-based readout, a relatively short timeline, quantifies the extent of tau aggregation, and also allows the assessment of cell viability. Furthermore, it can be easily adapted to different hiPSC lines or neuronal subtypes. Taken together, this complex and highly relevant approach can be routinely applied on a weekly basis in the screening funnels of several projects and generates data with a turnaround time of approximately five weeks.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Pluripotentes Induzidas / Doença de Alzheimer Limite: Humans Idioma: En Revista: SLAS Discov Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Pluripotentes Induzidas / Doença de Alzheimer Limite: Humans Idioma: En Revista: SLAS Discov Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha
...